Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fermaglich

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
The Patient|October 13, 2023
Determining Commonalities in the Experiences of Patients with Rare Diseases: A Qualitative Analysis of US Food and Drug Administration Patient Engagement SessionsCatherine Mease, Lewis J Fermaglich, Karen Jackler, et al.
Nature Reviews. Drug Discovery|December 12, 2023
Trends in drug development for amyotrophic lateral sclerosisSelma Kraft, Catherine Mease, Devanand Jillapalli, et al.
Orphanet Journal of Rare Diseases|March 22, 2024
Correction to: Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug developmentCatherine Mease, Kathleen L Miller, Lewis J Fermaglich, et al.
Orphanet Journal of Rare Diseases|February 25, 2024
Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug developmentCatherine Mease, Kathleen L Miller, Lewis J Fermaglich, et al.
Therapeutic Innovation & Regulatory Science|May 4, 2018
Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint StudiesLewis J Fermaglich, Ru Chen, Carol Y Kim, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
The Patient|October 13, 2023
Determining Commonalities in the Experiences of Patients with Rare Diseases: A Qualitative Analysis of US Food and Drug Administration Patient Engagement SessionsCatherine Mease, Lewis J Fermaglich, Karen Jackler, et al.
Nature Reviews. Drug Discovery|December 12, 2023
Trends in drug development for amyotrophic lateral sclerosisSelma Kraft, Catherine Mease, Devanand Jillapalli, et al.
Orphanet Journal of Rare Diseases|March 22, 2024
Correction to: Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug developmentCatherine Mease, Kathleen L Miller, Lewis J Fermaglich, et al.
Orphanet Journal of Rare Diseases|February 25, 2024
Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug developmentCatherine Mease, Kathleen L Miller, Lewis J Fermaglich, et al.
Therapeutic Innovation & Regulatory Science|May 4, 2018
Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint StudiesLewis J Fermaglich, Ru Chen, Carol Y Kim, et al.
Pageof 3